Overview
MGX market data
Price History
MGX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.36 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.68 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -384.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.13 – $3.95 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $46.3M · P/B 0.38 · P/S 2.07.
Company News
Wells Fargo Maintains Overweight on Metagenomi Therapeutics, Lowers Price Target to $7Benzinga · Aug 11, 2026, 1:09 PM
Metagenomi Q2 EPS $(0.73) Misses $(0.57) Estimate, Sales $(257.000K) Miss $2.960M EstimateBenzinga · Aug 10, 2026, 8:26 PM
8-K filing — Metagenomi Therapeutics, Inc. (MGX)SEC EDGAR · Aug 10, 2026, 8:10 PM
Chardan Capital Maintains Buy on Metagenomi Therapeutics, Lowers Price Target to $5Benzinga · Jul 7, 2026, 11:05 AM